JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma

NCT06954467 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: JS207
DRUG: JS007

Sponsor

Shanghai Junshi Bioscience Co., Ltd.